Targeted Therapy — With Existing Heart Disease

Not usually. Most patients with existing heart disease can receive targeted therapy — the question is which drug, at what dose, with what monitoring plan. The severity of your cardiac condition and the specific drug being considered are both part of that decision. A very recent heart attack or severely reduced heart function may require a pause in planning while your cardiac situation is stabilised, but this is assessed case by case, not as a blanket rule.

Several drug classes carry recognised cardiac effects. HER2-targeted drugs used in breast cancer can reduce the heart's pumping function in a proportion of patients. Drugs that target blood vessel growth can raise blood pressure. Some kinase inhibitors carry a risk of affecting the heart's electrical rhythm. The specific risk depends on the drug your oncologist has proposed, and they will explain what monitoring is planned for that drug before you start.

An ECG and an echocardiogram are the most common baseline assessments. A MUGA scan — a nuclear imaging test of heart function — is sometimes used instead of or alongside an echocardiogram. Your cardiologist may also want a full review of your current medications and, depending on your history, additional assessment before clearance is given. The aim is to establish a clear picture of your heart as it is now, so any change during treatment is visible against that reference point.

In most cases, no. Heart medications — including those for blood pressure, heart rhythm, and heart failure — are generally continued during cancer treatment. Some interactions between cardiac drugs and targeted therapies do exist, and your team will review your full medication list before you begin. Do not stop any heart medication without checking first. If your oncologist asks you to pause one, your cardiologist should be part of that conversation.

Report any new breathlessness, particularly if it comes on with less exertion than before or wakes you at night. Chest discomfort or chest pain should always be reported the same day. Swollen ankles or legs, palpitations, or a feeling of your heart racing or skipping are also symptoms your team needs to hear about. Fatigue that feels different from your usual treatment tiredness — especially alongside any of the above — is worth a call. These symptoms do not always mean something serious, but they need assessment promptly.

Often, yes. A reduction in the heart's pumping function caused by targeted therapy frequently improves after treatment is paused or the dose is adjusted, and in many cases cardiac medications are added to support recovery. This is one of the reasons regular monitoring exists — catching a change when it is still moderate means more options are available than if you wait until symptoms appear. Whether and how much function recovers depends on the drug, the severity of the drop, and how quickly it was detected.

There is no single answer, because it depends on how recent the heart attack was, how much cardiac function was affected, whether you have had a procedure such as a stent, and which cancer treatment is being proposed. ASCO and ESMO guidance recognises that both conditions carry their own urgency, and the decision involves your oncologist and cardiologist weighing that together. If you are in this situation, ask both teams to speak to each other directly rather than relaying information between them yourself.

It may, though this is usually decided in response to monitoring during treatment rather than in advance. If monitoring shows that your heart is being affected, your team will weigh reducing the dose or pausing treatment against the risk of under-treating the cancer. This is a real tradeoff and your oncologist should explain the reasoning behind any adjustment. In some cases the same cancer can be treated with a different drug that carries a lower cardiac risk — that option is worth asking about if cardiac concerns become a limiting factor.